Authors
Yun Wang, Els Van Nieuwenhuysen, Tone Skeie-Jensen, Toon Van Gorp, Anne-Kirsti Aksnes, Kari Myren, Ignace Vergote
Publication date
2023/9/1
Source
International Journal of Gynecologic Cancer
Volume
33
Issue
Suppl 3
Publisher
BMJ Specialist Journals
Description
Introduction/Background
Recurrent disease after secondary cytoreductive surgery for ovarian cancer (OC) is frequent. Radspherin is a novel alpha-emitting therapy. Alpha particles have high linear energy transfer and a radiation range < 100 µm (3–10 cell diameters), generating highly effective radiation with non-repairable double-strand DNA breaks in affected cells, killing micrometastasis and free-floating tumour cells after surgical resection, and reduced risk of toxicity compared with beta or gamma radiation.
Methodology
Here we report on the phase 1 study (NCT03732768) evaluating the recommended dose and safety of Radspherin in patients with a secondary R0 resection of platinum-sensitive recurrent epithelial OC. Radspherin is injected intraperitoneally two days after surgery. Dose escalation was performed at 1–2-4–7-MBq. Safety interim analysis after completion of the dose-limiting toxicity (DLT) period …
Scholar articles